MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases. Learn more
Product Pipeline Highlights
View full chart| Program (Target) | Indication | Lead Opt. | Pre- Clin. |
Ph 1 |
Ph 2 |
Ph 3 |
|---|---|---|---|---|---|---|
| AUTOIMMUNE | ||||||
| Teplizumab (Anti-CD3)(CD3) | Type 1 Diab. (PROTÉGÉ) | * | * | * | * | * |
| Pre-Diabetes (anticipated) | * | * | * | * | * | |
| Islet Transplantation | * | * | * | * | * | |
| 2nd Indication | * | * | * | * | * | |
| OtherOther(Undis.) | Inflammation | * | * | * | * | * |
| ONCOLOGY | ||||||
| MGAH22 (Anti-HER2)MGAH22 (Anti-HER2)(HER2) | Breast, other Solid Tumors | * | * | * | * | * |
| OtherOther(Undis.) | Multiple Solid Tumors | * | * | * | * | * |
| OtherOther(Undis.) | Multiple Solid Tumors | * | * | * | * | * |
| INFECTIOUS DISEASES | ||||||
| MGAWN1 and West Nile VirusMGAWN1 and West Nile Virus | West Nile Virus | * | * | * | * | * |
| OtherOther | Smallpox, Dengue, H5N1 | * | * | * | * | * |
Type 1 Diabetes
.gif){kind=logo}
Recently diagnosed with Type 1 Diabetes? Take action. Learn more: teplizumab
Learn more: ClinicalTrials.gov
Learn more: Protégé Encore site
Company Highlights
- Robust pipeline in autoimmunity, oncology and infectious diseases
- Global partnership with Eli Lilly for development of teplizumab
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
West Nile Virus
Paradigm - Phase 2 clinical study.Learn more: ClinicalTrials.gov Learn more: MGAWN1
Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn more